<DOC>
	<DOCNO>NCT02961257</DOCNO>
	<brief_summary>The purpose study evaluate incidence grade ≥ 3 neutropenia and/or neutropenic complication ( febrile neutropenia , neutropenic infection ) two schedule cabazitaxel ( bi-weekly versus tri-weekly ) plus prednisone elderly men ( ≥ 70 year ) mCRPC previously treat docetaxel-containing regimen .</brief_summary>
	<brief_title>Trial Evaluating Safety 2 Schedules Cabazitaxel Elderly Men With mCRPC Previously Treated With Docetaxel</brief_title>
	<detailed_description>Randomized , open-label , phase 3 trial mCRPC patient age ≥ 70 year . Treatment : - Arm A : cabazitaxel 25 mg/m² Day 1 3-week cycle plus daily prednisone - Arm B : cabazitaxel 16 mg/m² Day 1 Day 15 4-week cycle plus daily prednisone . - Treatment continue maximum 10 cycle unless documented disease progression unacceptable toxicity . - Standard cabazitaxel premedication use - Prophylactic G-CSF ( GRANOCYTE ) inject Day 3 Day 7 every cycle cabazitaxel neutrophil count &gt; 2000/mm3 , 3 day ) . - All new hormonal treatment , include ODM-201 , prior study entry allow . - Patients receive Radium-223 eligible study - Treatment LHRH discontinue . Exploratory assessment : CT-Scan ( abdominal/pelvic/chest ) whole body MRI Bone scan : screening , every 3 month EOT . FACT-P questionnaire : C1D1 , subsequent visit EOT Number subject : Total:170 ( 85 per arm ) Statistical analysis : A sample size 77 evaluable patient per arm achieve 80 % power detect 20 % difference G3 neutropenia incidence 2 arm . The incidence group cabazitaxel 25 mg/m2 q3w assume 32 % 12 % bi-weekly cabazitaxel arm . The test use two-sided Fisher 's exact test 0.05 significance level . Assuming 10 % non-evaluable patient , 85 patient include arm total 170 . Patients stratify accord G8 score previous ARtargeted agent ( abiraterone enzalutamide ) randomization .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patient age ≥ 70 year mCRPC previously treat docetaxel Sponsor Protocol : CABASTY Date 6thJune 2016 Version 4.0 Confidential Page 6 58 2 . Medical surgical castration castrate level testosterone ( &lt; 50 ng/dl ) 3 . Progressive disease accord physician judgement 4 . Histologically proven prostate carcinoma 5 . Health status allow use chemotherapy : G8 &gt; 14 ; G8 score ≤ 14 geriatric assessment conclude reversible impairment allow use chemotherapy 6 . ECOGPS 0 , 1 2 ( ECOGPS 2 related prostate cancer ) 7 . Adequate hematologic , liver renal function : 1 . Neutrophil count ≥1.5 109/L 2 . Haemoglobin ≥10 g/ dL 3 . Platelet count ≥100.109/L 4 . Total bilirubin ≤ 1 upper limit normal ( ULN ) 5 . Transaminases ≤ 1.5 ULN 6 . Serum creatinine ≤ 2.0 ULN 8 . Ongoing LHRH therapy study entry 9 . Signed informed consent 1 . History severe hypersensitivity reaction ( ≥grade 3 ) docetaxel 2 . History severe hypersensitivity reaction ( ≥grade 3 ) polysorbate 80 contain drug 3 . Uncontrolled severe illness medical condition ( include uncontrolled diabetes mellitus ) 4 . Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4/5 ( one week washout period necessary patient already treatment ) ( see Appendix E ) 5 . PS &gt; 2 related prostate cancer disease 6 . G8 ≤ 14 geriatric assessment contraindicate standard cabazitaxel regimen 7 . Concomitant vaccination yellow fever vaccine 8 . Patient regularly follow answer quality life questionnaires psychological , social , familial geographic reason 9 . Participation another clinical trial investigational drug within 30 day prior study enrolment .</criteria>
	<gender>Male</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>